芦可替尼治疗骨髓纤维化的真实世界非干预性长期上市后安全性研究
这项非干预性上市后安全性研究纳入462例骨髓纤维化患者(现用药者260例、新用药者32例、未暴露者170例),比较芦可替尼暴露与未暴露者的不良药物反应和严重不良事件发生率。新用药者与现用药者的不良药物反应发生率(每100患者年19.3 vs 19.6)和严重不良事件发生率(25.2 vs 25.0)相当。研究观察到的安全性特征与COMFORT/JUMP/EXPAND研究一致,支持芦可替尼用于骨髓纤维化的长期治疗。
要点
- 新用药者与现用药者不良药物反应发生率分别为每100患者年19.3与19.6,严重不良事件分别为25.2与25.0。
- 所有队列中最常见不良药物反应包括血小板减少、贫血、鼻出血、尿路感染和带状疱疹。
- 转用芦可替尼队列出血事件发生率21.6、严重/机会性感染34.5,高于其他队列。
核心结论
- 研究观察到的芦可替尼安全性特征与COMFORT/JUMP/EXPAND研究的安全性结果一致,支持芦可替尼用于骨髓纤维化患者的长期治疗。
研究设计与样本
- 这是一项非干预性、上市后安全性研究,主要目的是提供芦可替尼暴露或未暴露的成人骨髓纤维化患者的真实世界安全性数据(不良药物反应/严重不良事件发生率)。
- 共纳入462例患者,包括现用药者260例、新用药者32例、未暴露者170例(其中包含转用芦可替尼者57例)。
- 关键次要目标包括特殊关注事件(出血事件、严重/机会性感染、第二原发恶性肿瘤和死亡)的发生率和结局。
主要发现
- 新用药者与现用药者队列的不良药物反应发生率分别为每100患者年19.3与19.6,严重不良事件发生率分别为每100患者年25.2与25.0,两者相当。
- 所有队列中最常见的不良药物反应包括血小板减少、贫血、鼻出血、尿路感染和带状疱疹;最常见的严重不良事件包括贫血、肺炎、一般身体健康状况恶化、脓毒症和死亡。
- 转用芦可替尼队列的出血事件发生率为每100患者年21.6、严重/机会性感染发生率为每100患者年34.5,高于其他队列。
- 现用药者队列的第二原发恶性肿瘤发生率为每100患者年10.1,高于其他队列。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary objective of this non-interventional, post-authorisation safety study was to provide real-world safety data [incidence of adverse drug reactions (ADRs)/serious adverse events (SAEs)] on adult patients with myelofibrosis exposed/or not exposed to ruxolitinib. Key secondary objectives included the incidence/outcome of events of special interest (bleeding events, serious/opportunistic infections, second primary malignancies, and deaths). Overall, 462 patients were included [prevalent users = 260, new users = 32, non-exposed = 170 (inclusive of ruxolitinib-switch, n = 57)]. The exposure-adjusted incidence rates (per 100 patient-years) of ADRs (19·3 vs. 19·6) and SAEs (25·2 vs. 25·0) were comparable amongst new-users versus prevalent-users cohorts, respectively; most frequent ADRs across all cohorts included thrombocytopenia, anaemia, epistaxis, urinary tract infection, and herpes zoster. Anaemia, pneumonia, general physical health deterioration, sepsis, and death were the most frequent SAEs across all cohorts. Incidence rates of bleeding events (21·6) and serious/opportunistic infections (34·5) were higher in ruxolitinib-switch cohort versus other cohorts. The incidence rate of second primary malignancies was higher in the prevalent-users cohort (10·1) versus other cohorts. The observed safety profile of ruxolitinib in the present study along with the safety findings from the COMFORT/JUMP/EXPAND studies support the use of ruxolitinib for long-term treatment of patients with myelofibrosis.
引用
- Barraco F, Greil R, Herbrecht R, et al. Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis. Br J Haematol. 2020. PMID: 32583458. doi:10.1111/bjh.16729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。